Friday, September 10, 2021 Daily Archives

rEVolutionizing Acellular Therapies with Corning HYPER Technology

Deprecated: implode(): Passing glue string after array is deprecated. Swap the parameters in /var/www/wp-content/plugins/wistia-wordpress-oembed-plugin/wistia-anti-mangler.php on line 579

This webcast features: Amy C. Kauffman, PhD, Senior Development Engineer, Corning Life Sciences Extracellular vesicles (EVs) are a population of particles that are naturally released from cells. They are involved in intercellular communication, providing the necessary factors to mediate physiological events, and they are of high interest because of their potential for becoming the next generation of therapeutics. One potential area of interest is in generating an EV therapeutic in place of mesenchymal stem cell (MSC) therapies for pathological conditions…

Advantages of flexible manufacturing in advanced therapies

With rapid market growth and over 1220 ongoing clinical trials, the need for flexible alternatives is higher than ever. To meet this demand, advanced therapeutic developers are utilizing flexible manufacturing and single-use technologies. This is an abridged version of an article first published as part of the BioProcess Insider ebook, entitled: Cell and Gene Therapies — A 2021 Industry Update. To download the full report, click here. Utilizing flexible systems like premanufactured cleanrooms can reduce costs, construction timelines, and time…

Eli Lilly and industry criticize Biden’s drug pricing plan

Eli Lilly says the US Government’s latest pricing plan will restrict access of drugs to patients and restrict industry innovation. On Thursday, the US Department of Health and Human Services published a plan to address what it describes as prices for prescription drugs that are “higher than any comparable nation.” The report is based on three guiding principles for drug pricing reform: 1) To make drug prices more affordable and equitable for all consumers and throughout the health care system…